Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results


2012 | 7 | 3 | 362-365

Article title

Probiotic E.faecalis - adjuvant therapy in children with recurrent rhinosinusitis


Title variants

Languages of publication



Sinusitis is a frequent complication of respiratory tract infections. Probiotics are perceived to be useful in infections, allergies, and inflammations. Our prospective trial stratified 204 children with recurrent rhinosinusitis by age (2–11 years, 54m:64f; 12–18 years, 39m:47f) and assigned them to standard treatment (antibiotics, anticongestants) or additional 60 days Symbioflor-1 (SF1; Enterococcus faecalis 1.5–4.5x107 CFU). The number of sinusitis episodes was lower in SF1-treated patients (2.52±0.91) than among controls (3.27±1.36; p=0.01). Mean duration of the first sinusitis episode was 11.9±8.6 days with SF1, whereas it was 16.1±12.9 days in the younger controls (p=0.023) and 9.86±5.05 days in the elder controls (n.s.). Duration of subsequent sinusitis episodes was also shorter in SF1 patients (15.2±13.6 days) compared with controls (22.7±14.8 days; p=0.030). No adverse events were observed. Probiotic Enterococcus faecalis adjuvant to conventional therapy can reduce the number and duration of rhinosinusitis episodes in children and adolescents.










Physical description


1 - 6 - 2012
29 - 3 - 2012


  • Children’s Hospital, Goethe University, Theodor Stern Kai 7, D-60590, Frankfurt, Germany
  • Medical Hospital, Eberhard Karls University, Hoppe-Seyler-Straße 1, 72076, Tuebingen, Germany
  • inpharm consulting, Heidsieker Heide 114, 33739, Bielefeld, Germany
  • Medical Hospital, Eberhard Karls University, Hoppe-Seyler-Straße 1, 72076, Tuebingen, Germany
  • Children’s Hospital, Goethe University, Theodor Stern Kai 7, D-60590, Frankfurt, Germany


  • [1] W. Habermann, K. Zimmermann, H. Skarabis, R. Kunze, and V. Rusch. Reduction of acute recurrence in patients with chronic recurrent hypertrophic sinusitis by treatment with a bacterial immunostimulant (Enterococcus faecalis bacteriae of human origin). Drug Research, 2002, 52, 622–627 [PubMed]
  • [2] M.A. Rose, F. Stieglitz, A. Köksal, R. Schubert, J. Schulze, and S. Zielen. Efficacy of probiotic Lactobacillus GG on allergic sensitization and asthma in infants at risk. Clin. Exp. Allergy, 2010, 30(9), 1398–4058 http://dx.doi.org/10.1111/j.1365-2222.2010.03560.x[WoS][Crossref]
  • [3] Y. Ishida, F. Nakamura, H. Kanzato, D. Sawada, H. Hirata, A. Nishimura et al. Clinical effects of Lactobacillus acidophilus strain L-92 on perennial allergic rhinitis: a double-blind, placebo controlled study. J. Dairy Sci., 2005, 88(2), 527–533 http://dx.doi.org/10.3168/jds.S0022-0302(05)72714-4
  • [4] Z. Weizman, G. Asli, A. Alsheikh. Effect of a Probiotic Infant Formula on Infections in Child Care Centers: Comparison of Two Probiotic Agents. Pediatrics 2005, 115, 5–9
  • [5] M. Silva, N.V. Jacobus, C. Deneke, and S.L. Gorbach. Antimicrobial substance from a human lactobacillus strain. Antimicrob. Agents Chemother. 1987, 31(8), 1231–1233 [PubMed]
  • [6] E. Guillemard, F. Tondu, F. Lacoin, and J. Schrezenmeir. Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial. Br. J. Nutr. 2010, 103, 58–68 http://dx.doi.org/10.1017/S0007114509991395[Crossref][WoS]
  • [7] S.S. Mukerji, M.A. Pynnonen, H.M. Kim, A. Singer, M. Tabor, J.E. Terrell. Probiotics as adjunctive treatment for chronic rhinosinusitis: a randomized controlled trial. Otolaryngol. Head Neck Surg. 2009, 140, 202–208 http://dx.doi.org/10.1016/j.otohns.2008.11.020[WoS][Crossref]
  • [8] M. Giovannini, C. Agostoni, E. Riva, F. Salvini, A. Ruscitto, G.V. Zuccotti et al. A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing Lactobacillus casei in pre-school children with allergic asthma and/or rhinitis. Pediatr. Res., 2007, 62(2), 215–220 http://dx.doi.org/10.1203/PDR.0b013e3180a76d94[Crossref]
  • [9] E.M. Söderling, A.M. Marttinen, and A.L. Haukioja. Probiotic Lactobacilli interfere with Streptococcus mutans biofilm formation in vitro. Curr. Microbiol. 2011, 62(2), 618–622 http://dx.doi.org/10.1007/s00284-010-9752-9[Crossref]
  • [10] C. Forestier, D. Guelon, V. Cluytens, T. Gillart, J. Sirot, and C. de Champs. Oral probiotic and prevention of P. aeruginosa infections: a randomized, double-blind, placebo-controlled pilot study in intensive care unit patients. Critical Care, 2008, 12(3), R69 [WoS][Crossref]

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.